Keywords: واکنش محل تزریق; Mild; Moderate; Asthma; Lebrikizumab; AE; adverse event; AQLQ(S); Standardised Asthma Quality of Life Questionnaire; ATA; anti-therapeutic antibodies; FeNO; fractional exhaled nitric oxide; FEV1; forced expiratory volume in 1â¯s; HLGT; high level group t
مقالات ISI واکنش محل تزریق (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-
Keywords: واکنش محل تزریق; adalimumab; efficacy; guselkumab; hand and foot psoriasis; nail psoriasis; psoriasis; safety; scalp psoriasis; VOYAGE 1; VOYAGE 2; AE; adverse event; DLQI; Dermatology Life Quality Index; f-PGA; Fingernail Physician Global Assessment; HRQoL; health-relate
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, p
Keywords: واکنش محل تزریق; adalimumab; efficacy; guselkumab; interleukin-23; psoriasis; safety; switching; VOYAGE 1; VOYAGE 2; AE; adverse event; DLQI; Dermatology Life Quality Index; IGA; Investigator Global Assessment; IL; interleukin; ISR; injection site reaction; MACE; major ad
Proprotein convertase subtilisin/kexin 9Â inhibition in patients with familial hypercholesterolemia: Initial clinical experience
Keywords: واکنش محل تزریق; Cardiovascular disease; Familial hypercholesterolemia; PCSK9 inhibitors; Lipid-lowering therapy; Side effects; Injection site reaction;
Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
Keywords: واکنش محل تزریق; cDNA; complementary DNA; FI; fold increase; hs-CRP; high-sensitivity C-reactive protein; IL-1; interleukin 1; IL-6; interleukin 6; IL-1Ra; IL-1 receptor antagonist; IMM; indolent multiple myeloma; ISR; injection site reaction; MGUS; monoclonal gammopathy